CMPS Stock Analysis: Compass Pathways | NASDAQ
Medical Care Facilities | NASDAQ, USA | Market Cap: 1.596m USD | 12M Return: 86.3% | US20451W1018 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 35.8M
Qual. Beats: 1
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
COMPASS Pathways plc (NASDAQ: CMPS) is a London-headquartered biotechnology company developing psychedelic-based therapies for mental health conditions. Its lead candidate, COMP360 (psilocybin), is in Phase III clinical trials for treatment-resistant depression and Phase II trials for post-traumatic stress disorder and anorexia nervosa. The company was incorporated in 2020 and rebranded from COMPASS Rx Limited in August of that year, with operations spanning the United Kingdom and the United States.
The company operates within the emerging psychedelic medicine subsector of the healthcare industry, which focuses on researching Schedule I compounds like psilocybin for therapeutic applications. As a clinical-stage biotechnology firm, COMPASS Pathways relies on investor capital and partnership funding rather than product revenue, with its valuation tied to the progression of drug candidates through regulatory milestones with agencies such as the FDA and MHRA.
- COMP360 Phase III topline data readout for treatment-resistant depression
- FDA regulatory pathway clarity for psilocybin therapy approval
- Cash runway extension through potential equity offering dilutes shareholders
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.32 > 0.02 and ΔFCF/TA 18.58 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.32 > 3% & CFO -161.1m > Net Income -394.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (93.6m) vs 12m ago 0.32% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -75.60 > 6 (EBIT TTM -391.7m / Interest Expense TTM 5.18m) |
| A: 0.21 (Total Current Assets 475.7m - Total Current Liabilities 367.3m) / Total Assets 504.6m |
| B: -1.95 (Retained Earnings -985.2m / Total Assets 504.6m) |
| C: -0.98 (EBIT TTM -391.7m / Avg Total Assets 399.0m) |
| D: 0.20 (Book Value of Equity 84.5m / Total Liabilities 420.0m) |
| Altman-Z'' = -11.34 = D |
As of October 11, 2026, the stock is trading at USD 12.00 with a total of 2,281,757 shares traded. Over the past week, the price has changed by +0.84%, over one month by -20.90%, over three months by -11.76% and over the past year by +86.34%.
Current recommended Stop Loss: 10.60 (which is 11.7% or 2 ATR below the current price).
Compass Pathways has received a consensus analysts rating of 4.69. Therefore, it is recommended to buy CMPS.
- StrongBuy: 12
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 23.8 | 97.9% |
P/B = 22.5244
Revenue TTM = 0.0 USD
EBIT TTM = -391.7m USD
EBITDA TTM = -391.7m USD
Long Term Debt = 50.7m USD (from longTermDebt, last quarter)
Short Term Debt = 1.89m USD (from shortTermDebt, last quarter)
Debt = 58.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 3.90m
Net Debt = -374.8m USD (calculated: Debt 58.5m - CCE 433.3m)
Enterprise Value = 1.22b USD (1.60b + Debt 58.5m - CCE 433.3m)
Interest Coverage Ratio = -75.60 (Ebit TTM -391.7m / Interest Expense TTM 5.18m)
EV/FCF = -7.58x (Enterprise Value 1.22b / FCF TTM -161.1m)
FCF Yield = -13.20% (FCF TTM -161.1m / Enterprise Value 1.22b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 217k) / Revenue TTM)
Tobins Q-Ratio = 2.42 (Enterprise Value 1.22b / Total Assets 504.6m)
Interest Expense / Debt = 8.85% (Interest Expense 5.18m / Debt 58.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -309.4m (EBIT -391.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.30 (Total Current Assets 475.7m / Total Current Liabilities 367.3m)
Debt / Equity = 0.69 (Debt 58.5m / totalStockholderEquity, last quarter 84.5m)
Debt / EBITDA = 0.96 (negative EBITDA) (Net Debt -374.8m / EBITDA -391.7m)
Debt / FCF = 2.33 (negative FCF - burning cash) (Net Debt -374.8m / FCF TTM -161.1m)
Total Stockholder Equity = 99.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -98.78% (Net Income -394.2m / Total Assets 504.6m)
RoE = -398.2% (Net Income TTM -394.2m / Total Stockholder Equity 99.0m)
RoCE = -261.6% (out of range, set to none) (EBIT -391.7m / Capital Employed (Equity 99.0m + L.T.Debt 50.7m))
RoIC = -222.4% (out of range, set to none) (NOPAT -309.4m / Invested Capital 139.2m)
WACC = 13.09% (E(1.60b)/V(1.65b) * Re(13.31%) + D(58.5m)/V(1.65b) * Rd(8.85%) * (1-Tc(0.21)))
Discount Rate = 13.31% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 89.04 | Cagr: 18.24%
[DCF] Fair Price = unknown (Cash Flow -161.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.19 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.33 | Chg30d=+13.16% | Revisions=-25% | Analysts=4
EPS current Year (2026-12-31): EPS=-1.50 | Chg30d=+18.87% | Revisions=+0% | GrowthEPS=+14.9% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.43 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+4.8% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +0% (up=1, down=1)